- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00262834
Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer
A Pilot Study Evaluating Surrogates of Response to Short Term Oral Suberoylanilide Hydroxamic Acid (SAHA) in Women With Newly Diagnosed Breast Cancer
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
PRIMARY OBJECTIVE:
I. Determine the safety and tolerability of vorinostat in women undergoing conventional surgery for newly diagnosed stage I-III breast cancer.
OULINE: This is a multicenter, pilot study.
Patients receive oral vorinostat twice daily on days -3 to 0. Approximately 2 hours after the final dose of vorinostat, patients undergo surgical resection of the tumor on day 0.
After completion of study treatment, patients are followed for 30 days.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- No prior or concurrent hormonal therapy for breast cancer
- Histologically confirmed breast cancer, stage I-III disease, scheduled to undergo definitive surgery or other primary treatment (e.g., preoperative/neoadjuvant systemic treatment) for breast cancer
- ECOG 0-2 OR Karnofsky 60-100%
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Bilirubin normal
- AST and ALT ≤ 2.5 times upper limit of normal
- PT ≤ 14 seconds
- Creatinine normal
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No ongoing or active infection
- No psychiatric illness or social situation that would preclude study compliance
- No other uncontrolled intercurrent illness
- No history of allergic reaction attributed to compounds of similar chemical or biologic composition to vorinostat
- At least 30 days since prior hormone replacement therapy (e.g., estrogen and/or progestin)
- Concurrent vaginal hormone preparations (e.g., vagifem or estring) allowed
- No concurrent birth control pills
- No prior radiotherapy to the ipsilateral breast
- No prior or concurrent radiotherapy for breast cancer
- No prior or concurrent novel therapy for breast cancer
- At least 14 days since prior valproic acid or another histone deacetylase inhibitor
- No other concurrent investigational agents
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No other concurrent therapy for this cancer
- WBC ≥ 3,000/mm^3
Exclusion criteria:
- Patients must not be recieving any other investigational agents
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to SAHA.
- Patients may not be taking valproic acid or another histone deacetylase inhibitor for at least 2 weeks prior to initiating SAHA.
- Women who are pregnant.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Arm I
Patients receive oral vorinostat twice daily on days -3 to 0. Approximately 2 hours after the final dose of vorinostat, patients undergo conventional surgery of the tumor on day 0. After completion of study treatment, patients are followed for 30 days.
|
Given orally, conventional surgery to follow.
Andere namen:
Undergo conventional surgery
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Number of Participants With Adverse Events
Tijdsspanne: After 3 days of vorinostat
|
Participants were evaluated for adverse events due to vorinostat to assess if it was safe to give the drug prior to surgery.
17 of 25 participants who received vorinostat experienced at least 1 adverse event believed to be related to the study drug; no adverse events were severe, and the treatment was considered safe.
|
After 3 days of vorinostat
|
Change in Tissue Proliferation After 3 Days of Treatment
Tijdsspanne: After 3 days of vorinostat
|
Change in Ki-67 (a marker of tissue proliferation) by IHC compared to baseline in the treated (22 evaluable samples) or untreated patients (15 evaluable samples) were analyzed between groups.
Ki-67 is a protein in cells that increases as cellsprepare to divide into new cells.
A staining process can measure the percentage of tumor cells that are positive for Ki-67.
The more positive cells there are, the more quickly they are dividing and forming new cells.
|
After 3 days of vorinostat
|
Change in Tissue Apoptosis After 3 Days of Treatment
Tijdsspanne: Baseline and after 3 day of vorinostat
|
Change in cleaved caspase-3 (a marker of tissue apoptosis) by IHC compared to baseline in the treated (19 evaluable samples) or untreated patients (12 evaluable samples) were analyzed between groups.
Cleaved caspase-3 is a protein in cells involved in apoptosis (cell death).
|
Baseline and after 3 day of vorinostat
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Change in Tissue Histone Acetylation After 3 Days of Treatment
Tijdsspanne: Baseline and after 3 day of Vorinostat
|
To evaluate change from baseline in tissue histone acetylation in patients with primary breast cancer who received three days of Short Term Oral Suberoylanilide Hydroxamic Acid (SAHA) 300 mg PO bid immediately prior to definitive breast surgery or other primary treatment.
This is measured by Cumulative Methylation Index, which is reported as the sum of all %M for all genes.
%M= (methylated copies divided by methylated + unmethylated copies) x 100.
|
Baseline and after 3 day of Vorinostat
|
Change in Blood (Peripheral Blood Mononuclear Cells) Histone Acetylation After 3 Days of Treatment
Tijdsspanne: Baseline and after 3 day of Vorinostat
|
To evaluate baseline and change in histone acetylation in polymononuclear cells in patients with primary breast cancer who received three days of SAHA 300 mg PO bid immediately prior to definitive breast surgery or other primary treatment.
|
Baseline and after 3 day of Vorinostat
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Vered Stearns, Johns Hopkins University/Sidney Kimmel Cancer Center
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- NCI-2009-00098 (Register-ID: CTRP (Clinical Trial Reporting Program))
- P30CA006973 (Subsidie/contract van de Amerikaanse NIH)
- U01CA070095 (Subsidie/contract van de Amerikaanse NIH)
- 6914 (Andere identificatie: CTEP)
- CDR0000445404 (Andere identificatie: Clinical Data Repository (CT.gov))
- SKCCC J0504 (Andere identificatie: Johns Hopkins University/Sidney Kimmel Cancer Center)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Borstkanker
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University en andere medewerkersVoltooidDe klinische toepassingsgids van Conebeam Breast CTChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
University of Southern CaliforniaNational Cancer Institute (NCI)WervingLokaal gevorderd pancreasadenocarcinoom | Inoperabel pancreasadenocarcinoom | Fase III Pancreaskanker American Joint Committee on Cancer v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Nog niet aan het wervenAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
Klinische onderzoeken op vorinostat
-
Peter MacCallum Cancer Centre, AustraliaGlaxoSmithKline; Merck Sharp & Dohme LLCBeëindigdFolliculair lymfoom | Mantelcellymfoom | Marginale zone lymfoomAustralië
-
Groupe Francophone des MyelodysplasiesMerck Sharp & Dohme LLCBeëindigd
-
Virginia Commonwealth UniversityIngetrokken
-
Institut Claudius RegaudMerck Sharp & Dohme LLCBeëindigdKwaadaardige solide tumorFrankrijk
-
Johns Hopkins All Children's HospitalBeëindigdTumoren van het centrale zenuwstelselVerenigde Staten
-
National Center for Tumor Diseases, HeidelbergMerck Sharp & Dohme LLC; University Hospital HeidelbergVoltooid
-
Merck Sharp & Dohme LLCNiet meer beschikbaar
-
Medical University of GrazBeëindigdLeiomyosarcoom | Endometriale stromale tumoren | Carcinosarcomen BaarmoederOostenrijk
-
German Center for Neurodegenerative Diseases (DZNE)University Hospital, Bonn; University of GöttingenBeëindigd
-
Kanazawa UniversityOnbekendNiet-kleincellig longcarcinoomJapan